peptidase raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
== Research == In 1960 he commenced work in Cambridge on his PhD degree under the supervision of Fred Hoyle, and published his first scientific paper "On Graphite Particles as Interstellar Grains" in Monthly Notices of the Royal Astronomical Society in 1962. He was awarded a PhD degree in mathematics in 1963 and was elected a Fellow of Jesus College Cambridge in the same year. In the following year he was appointed a Staff Member of the Institute of Astronomy, Cambridge. Here he continued to work on the nature of interstellar dust, publishing many papers in this field, that led to a consideration of carbon-containing grains as well as the older silicate models. Wickramasinghe published the first definitive book on Interstellar Grains in 1967. He has made many contributions to this field, publishing over 350 papers in peer-reviewed journals, over 75 of which are in Nature. Hoyle and Wickramasinghe further proposed a radical kind of panspermia that included the claim that extraterrestrial life forms enter the Earth's atmosphere and were possibly responsible for epidemic outbreaks, new diseases, and genetic novelty that Hoyle and Wickramasinghe contended was necessary for macroevolution. Chandra Wickramasinghe had the longest-running collaboration with Fred Hoyle. Their publications on books and papers arguing for panspermia and a cosmic hypothesis of life are controversial and, in particular detail, essentially contra the scientific consensus in both astrophysics and biology.
=== Carbamate nerve agents === While the carbamate acetylcholinesterase inhibitors are commonly referred to as "carbamate insecticides" due to their generally high selectivity for insect acetylcholinesterase enzymes over the mammalian versions, the most potent compounds such as aldicarb and carbofuran are still capable of inhibiting mammalian acetylcholinesterase enzymes at low enough concentrations that they pose a significant risk of poisoning to humans, especially when used in large amounts for agricultural applications. Other carbamate based acetylcholinesterase inhibitors are known with even higher toxicity to humans, and some such as T-1123 and EA-3990 were investigated for potential military use as nerve agents. However, since all compounds of this type have a quaternary ammonium group with a permanent positive charge, they have poor blood–brain barrier penetration, and also are only stable as crystalline salts or aqueous solutions, and so were not considered to have suitable properties for weaponisation.
== Research areas == RCB engages in contemporary research at the interface of disciplines constituting biotechnology in its broadest definition. Research programmes aim to integrate science, engineering, medicine and agriculture in biotechnology and emphasize on their relevance to the regional societies. A broad range of research areas planned include:
=== Potential technology === A new family of LEDs are based on the semiconductors called perovskites. In 2018, less than four years after their discovery, the ability of perovskite LEDs (PLEDs) to produce light from electrons already rivaled those of the best performing OLEDs. They have a potential for cost-effectiveness as they can be processed from solution, a low-cost and low-tech method, which might allow perovskite-based devices that have large areas to be made with extremely low cost. Their efficiency is superior by eliminating non-radiative losses, in other words, elimination of recombination pathways that do not produce photons; or by solving outcoupling problem (prevalent for thin-film LEDs) or balancing charge carrier injection to increase the EQE (external quantum efficiency). The most up-to-date PLED devices have broken the performance barrier by shooting the EQE above 20%. In 2018, Cao et al. and Lin et al. independently published two papers on developing perovskite LEDs with EQE greater than 20%, which made these two papers a mile-stone in PLED development. Their device have similar planar structure, i.e. the active layer (perovskite) is sandwiched between two electrodes. To achieve a high EQE, they not only reduced non-radiative recombination, but also utilized their own, subtly different methods to improve the EQE. In the work of Cao et al., researchers targeted the outcoupling problem, which is that the optical physics of thin-film LEDs causes the majority of light generated by the semiconductor to be trapped in the device.
Sources: en.wikipedia.org
=== United Kingdom === In the United Kingdom all clinical scientists and biomedical scientists have had to be registered with the Health & Care Professions Council (HCPC) in order to work unsupervised, to develop through the careers grades of their profession and to use the protected titles of "clinical scientist" or "biomedical scientist". The HCPC registers nearly 200,000 healthcare professionals and while success in an approved degree course from an accredited university is sufficient for all other professions, both clinical scientists and biomedical scientists have post graduate training and no approved degree courses. Autonomous assessment of applicants in these two professions with subsequent certification for successful ones, is the only approved UK route to registration for them. "Clinical scientist", just as "biomedical scientist", is a protected title under the law (there is a £5000 fine for transgressors who fraudulently use the title without being registered by the state). The HCPC can strike people off the register for malpractice in just the same way as for doctors with the General Medical Council (GMC). Those who are working in trainee positions in the profession are permitted to use the title with an appropriate caveat, for example "pre-registration clinical scientist", "trainee clinical scientist", etc.
=== Potency === For equianalgesic dosing, when used sublingually, the potency of buprenorphine is about 40 to 70 times more potent than morphine. When used as a transdermal patch, the potency of buprenorphine may be 100 to 115 times greater than that of morphine.
MR-2034, or Mr-2034, also known as (–)-MR-2033, is a selective κ-opioid receptor (KOR) agonist of the benzomorphan family. Unlike other benzomorphan KOR agonists like cyclazocine and alazocine, MR-2034 does not also act on sigma receptors. In addition to the KOR, it has affinity for the μ-opioid receptor (MOR), but does not activate this receptor. The drug produces dose-dependent hallucinogenic and dysphoric effects in humans, as well as other effects such as dizziness, anxiety, and sedation. These effects can be blocked by the non-selective opioid receptor antagonist naloxone. The preceding findings led to the conclusion that the hallucinogenic and dysphoric effects of benzomorphans are mediated by the KOR rather than by sigma receptors. MR-2034 was first described in the scientific literature by 1975 and its hallucinogenic effects in humans were described in 1986.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.